Skip to main content

AMIA 2019 Annual Symposium Corporate Roundtable

AMIA corporate roundtables are fully catered events hosted by organizations looking to engage directly with leaders in the field. Participation in corporate roundtables is voluntary and based on your interest in the topic and availability. These events allow you to provide feedback on corporate strategies, inform product development, and learn what important biomedical and health informatics issues these companies are exploring.

Roundtables are by invitation only and are not eligible for CME/CE. Please select your top choices below, making sure your selections do not conflict with one another. You may select to join two roundtables from the registration list below. Click on the dates to learn more about the roundtables available at those times.

At-a-Glance AMIA 2019 Corporate Roundtable

Nov. 18, 12:00 p.m. – 1:30 p.m.

Data Rights and Institutional Review Board (IRB) Approval in the Age of Machine Learning
Cerner

Presenter: Tanuj K. Gupta, MD, MBA, Senior Director & Physician Executive, Cerner Intelligence

How can we create a responsible data environment where we can contribute healthcare data, where privacy and security of that data is protected, and where the data can be made available for continuous learning systems using artificial intelligence (AI) and machine learning (ML)? In this session, we will discuss ideas ranging from the most restrictive to least restrictive, to enabling a new age of clinical discovery.

Learning Objectives:

  • Review current state of data rights in healthcare
  • Review recent developments regarding data rights in healthcare
  • Discuss ways data rights may evolve with machine learning and artificial intelligence

Target Audience: C-Suite, Clinical Informaticists, Data Analysts, Researchers

Tell us about your big data, secondary use, and interoperability needs in informatics
InterSystems_Logo-cmyk.svgPREFERRED.png

Topic: InterSystems, along with producing the database technology underlying 2/3 of US EHR systems, provides large-scale interoperability, aggregation and transformation of health data from multiple acute, chronic, public, research, and patient sources. Through this technology, InterSystems provides a Unified Care Record for many of the largest hospitals and health systems, health information exchanges, and government health programs in the US and around the world. Some of our engagements involve big data processing, support for custom software, analytics and other secondary uses, decision support, and machine learning. We want to have a conversation with you at this roundtable to learn more about your needs and use cases in these areas, so that we can make our products and services ever more responsive to your needs in informatics practice.

Nov. 19, 12:00 p.m. – 1:30 p.m.

“Patient-First” Medication Management: Spotlight on Analytics
fbd-first-databank

Presenters: Anna Dover, PharmD, BCPS, Product Manager & John Doulis, Sr. Vice President, Clinical Solutions

Helping clinicians make safe and effective medication choices for their patients is the primary purpose of medication decision support systems. Unfortunately, “alert fatigue” – an all-too-common experience today – diminishes the effectives of such systems. It can also make it challenging for organizations to add new needed decision support into the clinical workflow. Analysis of clinical workflows and decision support provides many examples of over-alerting, under-alerting, insufficient information, and warnings presented at the wrong time. Clinicians are thus likely to ignore potentially important information or may be unaware of important patient information when they need it.

In this roundtable, we will:

  • Discuss how a “patient-first” approach to medication management that leverages additional inputs – such as lab results, genomic markers, and clinical scoring/surveillance systems – enables the presentation of meaningful and targeted decision support at the most appropriate place in the EHR clinical workflow.
  • Discuss how analytics can be leveraged to create patient-specific medication decision support. Combining knowledge of medication decision support structure with clinical workflows can provide improved insight into the efficacy of current and proposed strategies (e.g., using analytics to determine how to adjust the volume and appropriateness of interactions between Ondansetron and QT Prolonging Agents without impacting safety).
  • Solicit feedback about your current challenges in medication decision support implementation and performance and how to integrate more robust analytics in your process.

Target Audience: Pharmacists, Physicians, Nurses, Informaticists, CMIOs

Transforming the Experience of Healthcare with AI-Powered Proactive Solutions

3MM-MODAL

To mitigate the administrative burden on physicians experiencing up to 50% burnout rates, 3M M*Modal has accelerated innovation in conversational AI (artificial intelligence) solutions that are designed to create time to care by unifying clinical workflows and delivering proactive clinical insights. From spending nearly half their time on administrative tasks, physicians can now use an ambient, AI-based virtual assistant solution that can capture clinical documentation from conversational speech between the doctor and patient. Driving a progressive strategy, our clients can seamlessly transition from capturing the complete patient narrative by speech enabling the EHR, to effectively engaging clinicians with proactive nudges on care gaps, to a smart virtual assistant solution. Please join us on 11/19/19 at 12 noon to discuss how clients use our platform to improve outcomes, drive quality, and create time for patient care.

Key discussion points include:

  • Better understand market needs and their alignment with innovation in AI to drive proactive, in-workflow and real-time solutions that empower physicians and care teams across the continuum of care.
  • Leverage our advancement of speech-based solutions to widely-adopted Computer-Assisted Physician Documentation (CAPD) and a virtual assistant that brings conversational AI directly into the physician workflow for finishing routine tasks like EHR documentation, chart search, order entry, etc.
  • Take care management of patients and risk-capture strategies to the next level with a comprehensive Hierarchical Condition Category (HCC) solution that adopts a patient-centric, quality-focused approach to drive value-based care.
  • Sustainably engage physicians, improve quality of care, enhance the patient-physician relationship, and improve the overall experience of healthcare.

Target audience: CMO, CMIO, CIO, Population health, clinical informatics, decision support, care management and quality groups

Observational Research to Improve Patient Outcomes
MERCK_ifl_lg_rgb_tl_dkgry_USE ME.jpg

Presenters:
John Cai, MD, PhD, Executive Director, Real-world Data Analytics and Innovation, Merck
Kaushal Desai, PhD, Director, Real-world Data Analytics and Innovation, Merck
Sergio Eslava, MD, PhD, Director, Data Strategy and Platform, Merck
Carl Johnson, MD, Director, Medical Policy and Quality Research, Merck

How can collaborative network studies be conducted with harmonized real world data (RWD) to improve patient outcomes? This Roundtable explores why the quality and interoperability of digital healthcare data is critical to leverage the best analytic platforms and data science innovations that generate insights from RWD. RWD is defined by the United States Food and Drug Administration (FDA) as “data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources.” Real world evidence (RWE) is defined as “the clinical evidence about the usage and potential benefits or risks of a medical product derived from analysis of RWD.” Healthcare stakeholders and decision makers are embracing the use of RWE to fit multiple purposes that impact decisions made to improve patient outcomes. Confidence in observational research that uses RWD comes when researchers have high quality data that can be connected to fully understand the complete patient experience. The Roundtable will also facilitate dialogue to explore ways clinical informaticians, observational researchers, data scientists, and other healthcare stakeholders can collaborate and develop partnerships to conduct high-quality real world research that improves patient outcomes.

Target Audience: Enthusiasts of observational research, outcomes research, or data science, clinical research informaticians, CRIO, CMIO

Dammit Jim, I’m a Doctor, Not a Value Set Author!
Inteliigent Medical Objects logo resized.jpg

Presenter(s): Intelligent Medical Objects (IMO)

As the healthcare industry transitions to outcomes-based models, there is a growing imperative to identify and understand patient populations, support accurate clinical decision making and inform quality metrics and regulatory reporting. In this environment, healthcare organizations must rely on value sets to continuously define the inclusion or exclusion of specific patient cohorts within the vast sea of structured EHR data.

Most value sets, however, fail to deliver what’s needed – lacking the required granularity and accuracy, using up valuable clinician time, and poorly integrating with the EHR.

Thankfully, IMO doesn’t offer “most” value sets. At IMO, we believe value sets should be powered differently.

Join us for an interactive focus group on the future of value sets. We want to know what you need from these important tools, what IMO can do to improve your workflows, and how we can help your clinicians get back to doing what they do best – caring for patients. 

In this 45-minute session, we’ll seek your input and insights on IMO Precision Sets, our innovative value set solution that leverages clinically validated, always up to date, embeddable content that’s built upon IMO’s core foundational terminologies. We’ll explore the ways IMO Precision Sets can power precise care, create new value, and mitigate risk for organizations like yours, and take a closer look at key use cases driving demand for IMO Precision Sets, including oncology and opioid abuse.

Lunch and better paths to clinical insights will be served.

Target Audience: TBD